Skip to main
GYRE
GYRE logo

GYRE Stock Forecast & Price Target

GYRE Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Gyre Therapeutics Inc. is recognized for its strategic acquisition of generic nintedanib, which is expected to enhance its financial position by contributing additional capital to support its diverse operations in a challenging market environment. This acquisition not only fortifies Gyre's leadership in the interstitial lung disease (IPF) sector but also establishes the company as a significant provider of therapies targeting both lung and liver fibrosis. Furthermore, the company's commercial-stage products and ongoing pipeline development, including hydronidone for MASH-associated liver fibrosis, position it strongly for future growth in the pharmaceutical landscape.

Bears say

Gyre Therapeutics Inc. is facing a negative outlook primarily due to depressed forward multiples, attributed to current market volatility, which indicates investor uncertainty regarding future growth. Additionally, there is a lack of value associated with the commercial sales of pirfenidone in China, as it has been identified as a non-growth stage asset with revenue generation that has largely plateaued. Furthermore, the company's cash burn is a significant concern, as it could be heavily influenced by the varying stages of its development programs and the uncertain nature of potential milestone revenue from partnerships.

GYRE has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gyre Therapeutics Inc (GYRE) Forecast

Analysts have given GYRE a Strong Buy based on their latest research and market trends.

According to 2 analysts, GYRE has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gyre Therapeutics Inc (GYRE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.